Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19973540 | 1.00 | TRPV1 (0.36) | TRPV1BRD4CREBBPSLC6A2SLC6A4 | |
| SCHEMBL19973547 | 1.00 | TRPV1 (0.36) | TRPV1BRD4CREBBPSLC6A2SLC6A4 | |
| SCHEMBL21189240 | 0.85 | TSHR (0.37) | TRPV1ALOX15 | |
| SCHEMBL21189239 | 0.85 | TSHR (0.37) | TRPV1ALOX15 | |
| SCHEMBL26962575 | 0.81 | ADRA2A (0.40) | TRPV1 | |
| SCHEMBL27120222 | 0.81 | ADRA2A (0.40) | TRPV1 | |
| SCHEMBL19973588 | 0.80 | TP53 (0.39) | TRPV1 | |
| SCHEMBL19973590 | 0.80 | TP53 (0.39) | TRPV1 | |
| SCHEMBL19973589 | 0.80 | TP53 (0.39) | TRPV1 | |
| SCHEMBL20509848 | 0.80 | DRD2 (0.36) | TRPV1SLC6A2SLC6A4SLC6A3ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
| WO-2018052967-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | CBX8, HAVCR2, HCCS | TRPV1 3647/4885BRD4 7/4885CREBBP 864/4885 |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | CBX8, HAVCR2, HCCS | TRPV1 3647/4885BRD4 7/4885CREBBP 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.